logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9458092 B1

PDFFull Text
Date of Patent:
Oct. 04, 2016

Filed:

May. 07, 2014

α-substituted glycinamide derivative

Applicant:

Kissei Pharmaceutical Co., Ltd., Matsumoto-shi, Nagano, JP;

Inventors:

Hideaki Hirasawa, Azumino, JP;

Naohiro Kawamura, Joetsu, JP;

Junichi Kobayashi, Azumino, JP;

Assignee:

KISSEI PHARMACEUTICAL CO., LTD., Matsumoto-shi, JP;

Attorney:

Sughrue Mion, PLLC

Primary Examiner:

Pancham Bakshi

Int. Cl.
CPC ...
A61K 31/167 (2006.01); C07C 233/81 (2006.01); C07C 255/60 (2006.01); C07D 213/81 (2006.01); C07D 213/82 (2006.01); C07D 213/84 (2006.01); C07C 271/22 (2006.01); C07D 215/54 (2006.01); C07D 217/26 (2006.01); C07D 221/04 (2006.01); C07D 317/62 (2006.01); C07D 231/14 (2006.01); C07D 333/38 (2006.01); C07D 333/70 (2006.01); C07D 233/90 (2006.01); C07D 237/08 (2006.01); C07D 237/24 (2006.01); C07D 239/26 (2006.01); C07D 239/28 (2006.01); C07D 405/12 (2006.01); C07D 409/12 (2006.01); C07D 241/12 (2006.01); C07D 241/24 (2006.01); C07D 417/12 (2006.01); C07D 471/04 (2006.01); C07D 261/18 (2006.01); C07D 487/04 (2006.01); C07D 263/34 (2006.01); C07C 237/22 (2006.01); C07C 237/36 (2006.01); C07D 271/08 (2006.01); C07D 275/02 (2006.01); C07D 277/20 (2006.01); C07D 277/30 (2006.01); C07D 277/56 (2006.01); C07D 213/56 (2006.01); C07D 307/78 (2006.01); C07D 307/82 (2006.01);
U.S. Cl.
CPC ...
C07C 233/81 (2013.01); C07C 237/22 (2013.01); C07C 237/36 (2013.01); C07C 255/60 (2013.01); C07C 271/22 (2013.01); C07D 213/56 (2013.01); C07D 213/81 (2013.01); C07D 213/82 (2013.01); C07D 213/84 (2013.01); C07D 215/54 (2013.01); C07D 217/26 (2013.01); C07D 221/04 (2013.01); C07D 231/14 (2013.01); C07D 233/90 (2013.01); C07D 237/08 (2013.01); C07D 237/24 (2013.01); C07D 239/26 (2013.01); C07D 239/28 (2013.01); C07D 241/12 (2013.01); C07D 241/24 (2013.01); C07D 261/18 (2013.01); C07D 263/34 (2013.01); C07D 271/08 (2013.01); C07D 275/02 (2013.01); C07D 277/20 (2013.01); C07D 277/30 (2013.01); C07D 277/56 (2013.01); C07D 307/78 (2013.01); C07D 307/82 (2013.01); C07D 317/62 (2013.01); C07D 333/38 (2013.01); C07D 333/70 (2013.01); C07D 405/12 (2013.01); C07D 409/12 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07C 2101/02 (2013.01); C07C 2101/14 (2013.01); C07C 2102/08 (2013.01); C07C 2102/10 (2013.01);
Abstract

The present invention is to provide a novel α-substituted glycinamide derivative, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and a pharmaceutical use thereof. The present invention provides a compound represented by the general formula (I), which has TRPM8 inhibitory effects: [wherein Arepresents a Caryl and the like, Arepresents a Caryl and the like, X represents CH and the like, Y represents —CRR— and the like, Rand Rindependently represent a hydrogen atom and the like, Rand Rindependently represent a halogen atom and the like, n is 1 or 2], or a pharmaceutically acceptable salt thereof. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing diseases or symptoms caused by hyperexcitability or disorder of afferent neurons.

Find Patent Forward Citations

Loading…